David Greenway - Vertex Pharmaceuticals Director

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;padding-top: 25px;;'>VP</div>
VRTX -- USA Stock  

Report: 29th of July 2020  

Mr. David Greenway is Director of the company. He has two decades of experience in managing, financing and developing growth strategies for various TSX Venture Exchangeand Canadian Securities Exchangelisted companies. His key expertise lies in the management and development of junior public resource companies, especially in the mining sector, and the oil and gas sector. He has held directorships, senior management and business development positions, including his role as the chief executive officer of Stamper Oil Gas Corporationration, Chief Consolidated Gold Mines and SNS Silver Corporationration, and his board position in Mountain View Conservation Centre.
Age: 34  Director Since 2017      
617 341-6100  www.vrtx.com

Vertex Pharmaceuticals Management Efficiency

Vertex Pharmaceuticals has return on total asset (ROA) of 13.34 % which means that it generated profit of $13.34 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 27.02 %, meaning that it created $27.02 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Vertex Pharmaceuticals Return on Investment is fairly stable at the moment as compared to the past year. Vertex Pharmaceuticals reported Return on Investment of 20.56 in 2019. Return on Average Assets is likely to grow to 17.44 in 2020, whereas Return on Invested Capital is likely to drop (0.008739)  in 2020. Vertex Pharmaceuticals Total Assets are fairly stable at the moment as compared to the past year. Vertex Pharmaceuticals reported Total Assets of 8.32 Billion in 2019. Current Assets is likely to grow to about 5.2 B in 2020, whereas Revenue to Assets are likely to drop 0.46 in 2020. Current Liabilities is likely to grow to about 1.4 B in 2020, whereas Deposit Liabilities is likely to drop slightly above 65.7 M in 2020.
The company currently holds 532.95 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Vertex Pharmaceuticals has a current ratio of 3.47, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives


Anupam PuriDr Reddys Laboratories
Ravi BhoothalingamDr Reddys Laboratories
Helen HobbsPfizer Inc
Frances FergussonPfizer Inc
Herman MorrisPerrigo Company Plc
Dan LittmanPfizer Inc
Jeffrey KindlerPerrigo Company Plc
Frank DAmelioZoetis Inc
James SmithPfizer Inc
Sridar IyengarDr Reddys Laboratories
Stephen SangerPfizer Inc
Gregory NordenZoetis Inc
Adriane BrownAllergan Plc
Shantanu NarayenPfizer Inc
Theodore SamuelstoPerrigo Company Plc
James QuinceyPfizer Inc
Fred WeissAllergan Plc
James BloemAllergan Plc
Hans HaslerDr Reddys Laboratories
Wyllie CornwellPfizer Inc
Suzanne JohnsonPfizer Inc

Company Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in the United States and is traded on BATS Exchange. It employs 3000 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 3,000 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
98% Bullish
2% Bearish

Also Currentnly Active

<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.7em;padding-top:4px;;'>S</div>
Sold over 300 shares of
six days ago
Traded for 8.62
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>GM</div>
Sold over 100 shares of
six days ago
Traded for 25.24
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:0.9em;padding-top: 12px;;'>XOM</div>
Sold over 60 shares of
six days ago
Traded for 44.08
Also please take a look at World Market Map. Please also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page